Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues
Resumen:
Since the discovery of glucocorticoids (GCs), their important anti-inflammatory effect, rapid mechanism of action, low cost, and accessibility have made them one of the mainstays of treatment for Systemic lupus erythematosus (SLE). Although their use has allowed controlling the disease and reducing acute mortality in severe conditions, the implementation of a scheme based on high doses for long periods has inevitably been accompanied by an increase in adverse effects and infections, including long-term damage. The objective of this review is to answer some important questions that may arise from its use in daily clinical practice, and to propose a paradigm based on the use of methylprednisolone pulses followed by medium-low doses and a rapid decrease of prednisone.
| 2020 | |
|
SLE Damage Glucocorticoids Methylprednisolone Mortality Prednisone Prognosis Systemic lupus erythematosus GLUCOCORTICOIDES LUPUS ERITEMATOSO SISTÉMICO METILPREDNISOLONA PREDNISONA MORTALIDAD PRONÓSTICO |
|
| Inglés | |
| Universidad de la República | |
| COLIBRI | |
| https://hdl.handle.net/20.500.12008/55765 | |
| Acceso abierto | |
| Licencia Creative Commons Atribución (CC - By 4.0) |
| _version_ | 1872865108277854208 |
|---|---|
| author | Porta, Sabrina |
| author2 | Danza, Álvaro Arias Saavedra, Maira Carlomagno, Adriana Goizueta, María Cecilia Viviero, Florencia Ruiz-Irastorza, Guillermo |
| author2_role | author author author author author author |
| author_facet | Porta, Sabrina Danza, Álvaro Arias Saavedra, Maira Carlomagno, Adriana Goizueta, María Cecilia Viviero, Florencia Ruiz-Irastorza, Guillermo |
| author_role | author |
| bitstream.checksum.fl_str_mv | 6429389a7df7277b72b7924fdc7d47a9 a0ebbeafb9d2ec7cbb19d7137ebc392c c2be1a593bc16fa3ffa80ce838a200ca e7132498e7c1fe99f7096667baa99b25 b71af7df4e930ef05e21248456585200 |
| bitstream.checksumAlgorithm.fl_str_mv | MD5 MD5 MD5 MD5 MD5 |
| bitstream.url.fl_str_mv | http://localhost:8080/xmlui/bitstream/20.500.12008/55765/5/license.txt http://localhost:8080/xmlui/bitstream/20.500.12008/55765/2/license_url http://localhost:8080/xmlui/bitstream/20.500.12008/55765/3/license_text http://localhost:8080/xmlui/bitstream/20.500.12008/55765/4/license_rdf http://localhost:8080/xmlui/bitstream/20.500.12008/55765/1/Glucocorticoids+in+Systemic+Lupus+Erythematosus.pdf |
| collection | COLIBRI |
| dc.contributor.filiacion.none.fl_str_mv | Porta Sabrina, Hospital JM Ramos Mejía (Argentina). Departamento de Reumatología Danza Álvaro, Universidad de la República (Uruguay). Facultad de Medicina. Departamento de Medicina Interna Arias Saavedra Maira, Hospital JM Ramos Mejía (Argentina). Departamento de Reumatología Carlomagno Adriana, Universidad de la República (Uruguay). Facultad de Medicina. Departamento de Medicina Interna Goizueta María Cecilia, Sanatorio 9 de Julio (Argentina). Unidad de Enfermedades Autoinmunes Viviero Florencia, Hospital Privado de Comunidad (Argentina). Unidad de Enfermedades Autoinmunes Ruiz-Irastorza Guillermo, Hospital Universitario Cruces (España). Instituto de Investigación Sanitaria BioCruces Bizkaia. Unidad de Investigación de Enfermedades Autoinmunes; Universidad del País Vasco (España) |
| dc.creator.none.fl_str_mv | Porta, Sabrina Danza, Álvaro Arias Saavedra, Maira Carlomagno, Adriana Goizueta, María Cecilia Viviero, Florencia Ruiz-Irastorza, Guillermo |
| dc.date.accessioned.none.fl_str_mv | 2026-06-26T17:07:22Z |
| dc.date.available.none.fl_str_mv | 2026-06-26T17:07:22Z |
| dc.date.issued.none.fl_str_mv | 2020 |
| dc.description.abstract.none.fl_txt_mv | Since the discovery of glucocorticoids (GCs), their important anti-inflammatory effect, rapid mechanism of action, low cost, and accessibility have made them one of the mainstays of treatment for Systemic lupus erythematosus (SLE). Although their use has allowed controlling the disease and reducing acute mortality in severe conditions, the implementation of a scheme based on high doses for long periods has inevitably been accompanied by an increase in adverse effects and infections, including long-term damage. The objective of this review is to answer some important questions that may arise from its use in daily clinical practice, and to propose a paradigm based on the use of methylprednisolone pulses followed by medium-low doses and a rapid decrease of prednisone. |
| dc.format.extent.es.fl_str_mv | 13 p. |
| dc.format.mimetype.es.fl_str_mv | application/pdf |
| dc.identifier.citation.es.fl_str_mv | Porta S, Danza Á, Arias Saavedra M y otros. Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues. Journal of Clinical Medicine [en línea]. 2020;9(9). 13 p. |
| dc.identifier.doi.none.fl_str_mv | 10.3390/jcm9092709 |
| dc.identifier.eissn.none.fl_str_mv | 2077-0383 |
| dc.identifier.uri.none.fl_str_mv | https://hdl.handle.net/20.500.12008/55765 |
| dc.language.iso.none.fl_str_mv | en eng |
| dc.publisher.es.fl_str_mv | MDPI |
| dc.relation.none.fl_str_mv | Journal of Clinical Medicine. 2020;9(9) |
| dc.rights.license.none.fl_str_mv | Licencia Creative Commons Atribución (CC - By 4.0) |
| dc.rights.none.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.source.none.fl_str_mv | reponame:COLIBRI instname:Universidad de la República instacron:Universidad de la República |
| dc.subject.es.fl_str_mv | SLE Damage Glucocorticoids Methylprednisolone Mortality Prednisone Prognosis Systemic lupus erythematosus |
| dc.subject.other.es.fl_str_mv | GLUCOCORTICOIDES LUPUS ERITEMATOSO SISTÉMICO METILPREDNISOLONA PREDNISONA MORTALIDAD PRONÓSTICO |
| dc.title.none.fl_str_mv | Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues |
| dc.type.es.fl_str_mv | Artículo |
| dc.type.none.fl_str_mv | info:eu-repo/semantics/article |
| dc.type.version.none.fl_str_mv | info:eu-repo/semantics/publishedVersion |
| description | Since the discovery of glucocorticoids (GCs), their important anti-inflammatory effect, rapid mechanism of action, low cost, and accessibility have made them one of the mainstays of treatment for Systemic lupus erythematosus (SLE). Although their use has allowed controlling the disease and reducing acute mortality in severe conditions, the implementation of a scheme based on high doses for long periods has inevitably been accompanied by an increase in adverse effects and infections, including long-term damage. The objective of this review is to answer some important questions that may arise from its use in daily clinical practice, and to propose a paradigm based on the use of methylprednisolone pulses followed by medium-low doses and a rapid decrease of prednisone. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | COLIBRI_b5640b0bcd945294e241642c050b119e |
| identifier_str_mv | Porta S, Danza Á, Arias Saavedra M y otros. Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues. Journal of Clinical Medicine [en línea]. 2020;9(9). 13 p. 10.3390/jcm9092709 2077-0383 |
| instacron_str | Universidad de la República |
| institution | Universidad de la República |
| instname_str | Universidad de la República |
| language | eng |
| language_invalid_str_mv | en |
| network_acronym_str | COLIBRI |
| network_name_str | COLIBRI |
| oai_identifier_str | oai:colibri.udelar.edu.uy:20.500.12008/55765 |
| publishDate | 2020 |
| reponame_str | COLIBRI |
| repository.mail.fl_str_mv | karina.camps@seciu.edu.uy |
| repository.name.fl_str_mv | COLIBRI - Universidad de la República |
| repository_id_str | 4771 |
| rights_invalid_str_mv | Licencia Creative Commons Atribución (CC - By 4.0) |
| spelling | Porta Sabrina, Hospital JM Ramos Mejía (Argentina). Departamento de ReumatologíaDanza Álvaro, Universidad de la República (Uruguay). Facultad de Medicina. Departamento de Medicina InternaArias Saavedra Maira, Hospital JM Ramos Mejía (Argentina). Departamento de ReumatologíaCarlomagno Adriana, Universidad de la República (Uruguay). Facultad de Medicina. Departamento de Medicina InternaGoizueta María Cecilia, Sanatorio 9 de Julio (Argentina). Unidad de Enfermedades AutoinmunesViviero Florencia, Hospital Privado de Comunidad (Argentina). Unidad de Enfermedades AutoinmunesRuiz-Irastorza Guillermo, Hospital Universitario Cruces (España). Instituto de Investigación Sanitaria BioCruces Bizkaia. Unidad de Investigación de Enfermedades Autoinmunes; Universidad del País Vasco (España)2026-06-26T17:07:22Z2026-06-26T17:07:22Z2020Porta S, Danza Á, Arias Saavedra M y otros. Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues. Journal of Clinical Medicine [en línea]. 2020;9(9). 13 p.https://hdl.handle.net/20.500.12008/5576510.3390/jcm90927092077-0383Since the discovery of glucocorticoids (GCs), their important anti-inflammatory effect, rapid mechanism of action, low cost, and accessibility have made them one of the mainstays of treatment for Systemic lupus erythematosus (SLE). Although their use has allowed controlling the disease and reducing acute mortality in severe conditions, the implementation of a scheme based on high doses for long periods has inevitably been accompanied by an increase in adverse effects and infections, including long-term damage. The objective of this review is to answer some important questions that may arise from its use in daily clinical practice, and to propose a paradigm based on the use of methylprednisolone pulses followed by medium-low doses and a rapid decrease of prednisone.Submitted by Almiñana María Cecilia (marialminana@gmail.com) on 2026-06-26T13:21:52Z No. of bitstreams: 2 license_rdf: 25630 bytes, checksum: e7132498e7c1fe99f7096667baa99b25 (MD5) Glucocorticoids in Systemic Lupus Erythematosus.pdf: 19066810 bytes, checksum: b71af7df4e930ef05e21248456585200 (MD5)Approved for entry into archive by Almiñana María Cecilia (marialminana@gmail.com) on 2026-06-26T15:28:13Z (GMT) No. of bitstreams: 2 license_rdf: 25630 bytes, checksum: e7132498e7c1fe99f7096667baa99b25 (MD5) Glucocorticoids in Systemic Lupus Erythematosus.pdf: 19066810 bytes, checksum: b71af7df4e930ef05e21248456585200 (MD5)Made available in DSpace by Luna Fabiana (fabiana.luna@seciu.edu.uy) on 2026-06-26T17:07:22Z (GMT). No. of bitstreams: 2 license_rdf: 25630 bytes, checksum: e7132498e7c1fe99f7096667baa99b25 (MD5) Glucocorticoids in Systemic Lupus Erythematosus.pdf: 19066810 bytes, checksum: b71af7df4e930ef05e21248456585200 (MD5) Previous issue date: 202013 p.application/pdfenengMDPIJournal of Clinical Medicine. 2020;9(9)Las obras depositadas en el Repositorio se rigen por la Ordenanza de los Derechos de la Propiedad Intelectual de la Universidad de la República.(Res. Nº 91 de C.D.C. de 8/III/1994 – D.O. 7/IV/1994) y por la Ordenanza del Repositorio Abierto de la Universidad de la República (Res. Nº 16 de C.D.C. de 07/10/2014)info:eu-repo/semantics/openAccessLicencia Creative Commons Atribución (CC - By 4.0)SLEDamageGlucocorticoidsMethylprednisoloneMortalityPrednisonePrognosisSystemic lupus erythematosusGLUCOCORTICOIDESLUPUS ERITEMATOSO SISTÉMICOMETILPREDNISOLONAPREDNISONAMORTALIDADPRONÓSTICOGlucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some IssuesArtículoinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionreponame:COLIBRIinstname:Universidad de la Repúblicainstacron:Universidad de la RepúblicaPorta, SabrinaDanza, ÁlvaroArias Saavedra, MairaCarlomagno, AdrianaGoizueta, María CeciliaViviero, FlorenciaRuiz-Irastorza, GuillermoLICENSElicense.txtlicense.txttext/plain; charset=utf-84267http://localhost:8080/xmlui/bitstream/20.500.12008/55765/5/license.txt6429389a7df7277b72b7924fdc7d47a9MD55CC-LICENSElicense_urllicense_urltext/plain; charset=utf-844http://localhost:8080/xmlui/bitstream/20.500.12008/55765/2/license_urla0ebbeafb9d2ec7cbb19d7137ebc392cMD52license_textlicense_texttext/html; charset=utf-831351http://localhost:8080/xmlui/bitstream/20.500.12008/55765/3/license_textc2be1a593bc16fa3ffa80ce838a200caMD53license_rdflicense_rdfapplication/rdf+xml; charset=utf-825630http://localhost:8080/xmlui/bitstream/20.500.12008/55765/4/license_rdfe7132498e7c1fe99f7096667baa99b25MD54ORIGINALGlucocorticoids in Systemic Lupus Erythematosus.pdfGlucocorticoids in Systemic Lupus Erythematosus.pdfapplication/pdf19066810http://localhost:8080/xmlui/bitstream/20.500.12008/55765/1/Glucocorticoids+in+Systemic+Lupus+Erythematosus.pdfb71af7df4e930ef05e21248456585200MD5120.500.12008/557652026-06-26 14:07:23.009oai:colibri.udelar.edu.uy:20.500.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Institucionalhttps://www.colibri.udelar.edu.uyUniversidad públicahttps://udelar.edu.uy/https://www.colibri.udelar.edu.uy/oai/requestkarina.camps@seciu.edu.uyUruguayopendoar:47712026-06-26T17:07:23COLIBRI - Universidad de la Repúblicafalse |
| spellingShingle | Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues Porta, Sabrina SLE Damage Glucocorticoids Methylprednisolone Mortality Prednisone Prognosis Systemic lupus erythematosus GLUCOCORTICOIDES LUPUS ERITEMATOSO SISTÉMICO METILPREDNISOLONA PREDNISONA MORTALIDAD PRONÓSTICO |
| status_str | publishedVersion |
| title | Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues |
| title_full | Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues |
| title_fullStr | Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues |
| title_full_unstemmed | Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues |
| title_short | Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues |
| title_sort | Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues |
| topic | SLE Damage Glucocorticoids Methylprednisolone Mortality Prednisone Prognosis Systemic lupus erythematosus GLUCOCORTICOIDES LUPUS ERITEMATOSO SISTÉMICO METILPREDNISOLONA PREDNISONA MORTALIDAD PRONÓSTICO |
| url | https://hdl.handle.net/20.500.12008/55765 |
